Oxford, UK, September 2026. OGT, a leading global provider of genomic research and diagnostic solutions, today announced the expansion of its SureSeq™ Universal NGS Unique Dual Index (UDI) range, enabling laboratories to multiplex up to 384 uniquely indexed samples in a single sequencing run. Compatible with existing SureSeq workflows and software, expanded UDI capabilities provide a straightforward path for laboratories looking to scale throughput while maintaining established processes and data quality.
As sample volumes continue to increase, many high-throughput laboratories are looking for ways to maximize their NGS capacity without needing to modify existing workflows. The expanded SureSeq Universal NGS UDI offering addresses this challenge by increasing indexing capacity from 96 to 384 unique dual indexes. With this expansion, laboratories can process more samples and better utilize high-capacity Illumina sequencing systems, increasing operational efficiency and reducing per-sample run costs.
Designed to integrate seamlessly with existing SureSeq workflows, the expanded UDI capability eliminates the need to modify workflow design. Laboratories can scale operations while continuing to work with the SureSeq solutions they already know and trust.
"As sequencing demand continues to grow, laboratories need practical ways to increase throughput without adding complexity," said Gareth Thomson, Executive Vice President of Commercial Operations at OGT. "By expanding SureSeq Universal NGS indexing capacity to 384 samples per run, we're helping laboratories reduce batching constraints and costs per sample to maximize the value of their existing sequencing infrastructure. All the while, customers can still expect the same workflow consistency and performance they rely on from SureSeq."
The expanded SureSeq Universal NGS UDI offering is designed to deliver performance equivalent to existing UDI 1–96 index sets while supporting confident, multiplexed sequencing through unique dual indexing. With the expanded offering of available UDIs, OGT continues its commitment to providing scalable genomic solutions created by scientists, for scientists.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 30 years at the forefront of genetic endeavor, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell® IVDR Prenatal FISH Probe Kits: For in vitro diagnostic use. For laboratory professional use only. Not intended for use as a stand-alone diagnostic. Refer to each individual FISH probe kit’s Instructions for Use for their specific Intended Purpose, Indications, and Limitations.
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey."* Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
* "Healthcare journey" is a trademark of Sysmex Corporation, registered in Japan.
Enables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs.
Read
Through this partnership, SureSeq™ NGS panel users can gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.
Read
Improving upon existing SureSeq™ technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples
Read
Visit International site
Visit USA site